TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Tango Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$23.53+1.49 (+6.76%)

Close on Oct 19, 2026

Market cap: $3.53B
P/E (TTM): –
Dividend yield: –

Tango Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	62	42	37	25	37	7.66
Research & Development	132	144	115	106	78	50
General & Administrative	42	44	36	30	18	9.87
Operating Expenses	174	188	151	136	95	60
Operating Income	-111	-146	-114	-111	-58	-52
Other Non-Operating Income	9.70	16	13	2.95	0.25	0.23
Asset Impairment Charges	0	0	0	0	0	–
Pretax Income	-102	-130	-102	-108	-58	-52
Income Tax Expense	0.00	0.21	0.13	0.05	0.29	0
Net Income incl. Noncontrolling Interests	-102	-130	-102	–	–	–
Net Income	-102	-130	-102	-108	-58	-52
EPS (Basic)(per share)	-0.87	-1.19	-1.08	-1.23	-0.94	-1.63
EPS (Diluted)(per share)	-0.87	-1.19	-1.08	-1.23	-0.94	-1.63
Shares Outstanding (Basic, Weighted)(shares)	116	109	95	88	62	32
Shares Outstanding (Diluted, Weighted)(shares)	116	109	95	88	62	32
Net Interest Income	5.63	7.89	6.62	1.46	0.50	0.11

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -253.4%
Net margin: -229.9%
Return on equity, FY2025: -37.2%

Financial strength

Current ratio: 50.82
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1702.3%

Valuation

P/E ratio: –
Price to sales: 65.54
Price to book: 3.44
Dividend yield: –